Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09LRA
|
||||
| Former ID |
DIB020605
|
||||
| Drug Name |
omega-conotoxin GVIA
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539645] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C120H188N38O43S6
|
||||
| InChI |
InChI=1S/C120H188N38O43S6/c1-53(165)91(114(197)138-66(10-4-6-26-122)95(178)136-68(12-8-28-132-120(129)130)98(181)149-81(49-204)107(190)139-69(93(126)176)29-55-13-19-58(167)20-14-55)154-101(184)71(31-57-17-23-60(169)24-18-57)142-112(195)86-33-62(171)39-157(86)116(199)73(36-89(125)174)143-108(191)82(50-205)151-104(187)75(42-160)144-96(179)67(11-7-27-131-119(127)128)137-106(189)80(48-203)153-110(193)84(52-207)150-100(183)72(35-88(124)173)141-99(182)70(30-56-15-21-59(168)22-16-56)140-103(186)77(44-162)146-115(198)92(54(2)166)155-113(196)87-34-63(172)40-158(87)118(201)79(46-164)148-109(192)83(51-206)152-105(188)76(43-161)145-102(185)74(41-159)134-90(175)37-133-111(194)85-32-61(170)38-156(85)117(200)78(45-163)147-97(180)65(9-3-5-25-121)135-94(177)64(123)47-202/h13-24,53-54,61-87,91-92,159-172,202-207H,3-12,25-52,121-123H2,1-2H3,(H2,124,173)(H2,125,174)(H2,126,176)(H,133,194)(H,134,175)(H,135,177)(H,136,178)(H,137,189)(H,138,197)(H,139,190)(H,140,186)(H,141,182)(H,142,195)(H,143,191)(H,144,179)(H,145,185)(H,146,198)(H,147,180)(H,148,192)(H,149,181)(H,150,183)(H,151,187)(H,152,188)(H,153,193)(H,154,184)(H,155,196)(H4,127,128,131)(H4,129,130,132)/t53-,54-,61-,62-,63-,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,91+,92+/m1/s1
|
||||
| InChIKey |
XJKFZICVAPPHCK-NZPQQUJLSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent N-type calcium channel | Target Info | Blocker (channel blocker) | [525847] | |
| Voltage-dependent P/Q-type calcium channel alpha-1A subunit | Target Info | Blocker (channel blocker) | [525847] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| Synaptic vesicle cycle | |||||
| Retrograde endocannabinoid signaling | |||||
| Cholinergic synapse | |||||
| Serotonergic synapse | |||||
| GABAergic synapse | |||||
| Dopaminergic synapse | |||||
| Taste transduction | |||||
| Type II diabetes mellitus | |||||
| Morphine addiction | |||||
| Nicotine addictionhsa04010:MAPK signaling pathway | |||||
| Glutamatergic synapse | |||||
| Long-term depression | |||||
| Nicotine addiction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | |||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group II pathway | |||||
| Thyrotropin-releasing hormone receptor signaling pathway | |||||
| Endogenous cannabinoid signaling | |||||
| GABA-B receptor II signalingP00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| GABA-B receptor II signaling | |||||
| PathWhiz Pathway | Pancreas Function | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.